Who are Tunlametinib plus Vemurafenib's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Encorafenib and Binimetinib.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tunlametinib-plus-vemurafenib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Tunlametinib plus Vemurafenib — Competitive Intelligence Brief

Tunlametinib plus Vemurafenib (Tunlametinib plus Vemurafenib) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: BRAF inhibitor + MEK inhibitor combination. Area: Oncology.

phase 3 BRAF inhibitor + MEK inhibitor combination BRAF V600E and MEK1/2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Tunlametinib plus Vemurafenib (Tunlametinib plus Vemurafenib) — Shanghai Kechow Pharma, Inc.. This combination blocks BRAF and MEK signaling in the MAPK pathway to inhibit growth of BRAF-mutant melanoma and other cancers.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tunlametinib plus Vemurafenib TARGET	Tunlametinib plus Vemurafenib	Shanghai Kechow Pharma, Inc.	phase 3	BRAF inhibitor + MEK inhibitor combination	BRAF V600E and MEK1/2
Encorafenib and Binimetinib	Encorafenib and Binimetinib	Pierre Fabre Medicament	phase 3	BRAF inhibitor + MEK inhibitor combination	BRAF V600E/K and MEK1/2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (BRAF inhibitor + MEK inhibitor combination class)

Pierre Fabre Medicament · 1 drug in this class
Shanghai Kechow Pharma, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tunlametinib plus Vemurafenib — Competitive Intelligence Brief. https://druglandscape.com/ci/tunlametinib-plus-vemurafenib. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab